Related Experiment Video
Updated: Jun 29, 2025
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition
Hisham A Badreldin1,2,3, Nada Alsuhebany1,2,3, Mohammed Alzahrani1,2,3
1Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Abstract:
Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased risk of gastrointestinal bleeding and unsuitability for patients with mechanical heart valves. Recent research has highlighted Factor XI (FXI) as a promising anticoagulation target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis. This review provides a comprehensive analysis of abelacimab, examining its clinical pharmacology and its pharmacokinetic and pharmacodynamic properties. It scrutinizes abelacimab's safety profile and key monitoring parameters. The current evidence supporting its use and potential future research strengthening its position in anticoagulant therapy is also discussed. The objective is to enhance understanding and contribute to discussions around developing safer anticoagulants, particularly for patients at risk for thrombosis.
Insights
Abelacimab, a novel Factor XI inhibitor, shows promise for safer anticoagulation by targeting pathological thrombosis while preserving normal hemostasis. This approach may offer an improved alternative for patients at risk of blood clots.
Area of Science:
- Pharmacology
- Hematology
- Thrombosis Research
Background:
- Direct Oral Anticoagulants (DOACs) offer improved anticoagulation but carry risks like gastrointestinal bleeding.
- Factor XI (FXI) is a potential target for anticoagulation due to its role in thrombosis and minimal impact on hemostasis.
- Current anticoagulants have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the clinical pharmacology, pharmacokinetics, and pharmacodynamics of abelacimab, an FXI inhibitor.
- To evaluate the safety profile and monitoring parameters of abelacimab.
- To discuss current evidence and future research directions for abelacimab in anticoagulation therapy.
Main Methods:
- Comprehensive literature review of clinical pharmacology studies.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Evaluation of safety data and monitoring strategies for abelacimab.
Main Results:
- Abelacimab demonstrates FXI inhibition, potentially sparing normal hemostasis.
- Early clinical data suggest a favorable safety profile.
- Pharmacological properties support its potential as a targeted anticoagulant.
Conclusions:
- Abelacimab represents a promising new class of anticoagulants targeting FXI.
- Its ability to spare hemostasis could lead to reduced bleeding complications.
- Further research is warranted to solidify abelacimab's role in preventing thrombosis.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...